ID

26224

Descrizione

Study ID: 101468/125 Clinical Study ID: SKF-101468/125 Study Title: A double-blind, multicentre, flexible dose, L-dopa controlled study of ropinirole to investigate A) neuroprotective effect as measured by 3D PET scanning, and B) ophthalmological safety, in patients with early Parkinson’s disease Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: requip Study Indication: Restless Legs Syndrome

Keywords

versioni (1)
  1. 12/10/17 12/10/17 -
Titolare del copyright

GlaxoSmithKline

Caricato su

12 ottobre 2017

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY-NC 3.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

L-dopa controlled study of ropinirole, neuroprotective effect and ophthalmological safety in early Parkinson’s disease 101468/125 Module 1 Concomitant Medication/Adverse Experiences

Inglese

L-dopa controlled study of ropinirole, neuroprotective effect and ophthalmological safety in early Parkinson’s disease 101468/125 Module 1 Concomitant Medication/Adverse Experiences

1 moduli  
Concomitant Medication Information
Descrizione

Concomitant Medication Information

Concomitant Medication Information noticed
Descrizione

Concomitant Medication Information

Tipo di dati

boolean

Concomitant Medication
Descrizione

Concomitant Medication

Drug Name (Trade Name Preferred)
Descrizione

Drug Name (Trade Name Preferred)

Tipo di dati

text

Total daily dose (e.g. 500 mg)
Descrizione

Total daily dose

Tipo di dati

integer

Unità di misura
  • mg
mg
Medical Condition
Descrizione

Medical Condition

Tipo di dati

text

Approximate Start Date
Descrizione

Approximate Start Date

Tipo di dati

date

End Date (leave blank if continuing)
Descrizione

End Date

Tipo di dati

date

Continuing
Descrizione

Continuing

Tipo di dati

boolean

For SB
Descrizione

For SB

Tipo di dati

text

Adverse Experiences
Descrizione

Adverse Experiences

Definition of serious adverse experiences
Descrizione

A serious adverse experience is any experience which is -fatal -life threatening - disabling - incapacitating - results in hospitalization - prolongs a hospital stay - associated with congenital abnormality, carcinoma or overdose

Tipo di dati

boolean

Adverse Experience Details
Descrizione

Adverse Experience Details

Experience
Descrizione

Experience

Tipo di dati

text

For SB
Descrizione

For SB

Tipo di dati

text

Date Started
Descrizione

Date Started

Tipo di dati

date

Date Stopped
Descrizione

Date Stopped

Tipo di dati

date

Duration (if less than 24hrs)
Descrizione

Duration

Tipo di dati

float

Unità di misura
  • hrs
hrs
Experience continuing
Descrizione

Experience continuing

Tipo di dati

boolean

Course: Continuous
Descrizione

Course

Tipo di dati

boolean

If No, no. of episodes
Descrizione

No. of episodes

Tipo di dati

integer

Intensity
Descrizione

Intensity

Tipo di dati

text

Action taken on Study Medication
Descrizione

Action taken on Study Medication

Tipo di dati

integer

Suspected Relationship
Descrizione

Suspected Relationship

Tipo di dati

text

Corrective Therapy
Descrizione

Corrective Therapy

Tipo di dati

text

Do you consider this a serious adverse experience by the definitions on the tab?
Descrizione

If patient died complete Form D

Tipo di dati

integer

Investigator´s Signature
Descrizione

Investigator´s Signature

Investigator´s Signature
Descrizione

Investigator´s Signature

Tipo di dati

text

Date
Descrizione

Date

Tipo di dati

date

Ritorna all'inizio della pagina

Similar models

L-dopa controlled study of ropinirole, neuroprotective effect and ophthalmological safety in early Parkinson’s disease 101468/125 Module 1 Concomitant Medication/Adverse Experiences

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
Concomitant Medication Information
Concomitant Medication Information
Item
Concomitant Medication Information noticed
boolean
Item Group
Concomitant Medication
Drug Name (Trade Name Preferred)
Item
Drug Name (Trade Name Preferred)
text
Total daily dose
Item
Total daily dose (e.g. 500 mg)
integer
Medical Condition
Item
Medical Condition
text
Approximate Start Date
Item
Approximate Start Date
date
End Date
Item
End Date (leave blank if continuing)
date
Continuing
Item
Continuing
boolean
For SB
Item
For SB
text
Item Group
Adverse Experiences
Definition of serious adverse experiences
Item
Definition of serious adverse experiences
boolean
Item Group
Adverse Experience Details
Experience
Item
Experience
text
For SB
Item
For SB
text
Date Started
Item
Date Started
date
Date Stopped
Item
Date Stopped
date
Duration
Item
Duration (if less than 24hrs)
float
Experience continuing
Item
Experience continuing
boolean
Course
Item
Course: Continuous
boolean
No. of episodes
Item
If No, no. of episodes
integer
Item
Intensity
text
Intensity
Code List
Intensity
CL Item
Mild (1)
CL Item
Moderate (2)
CL Item
Severe (3)
Item
Action taken on Study Medication
integer
Action taken on Study Medication
Code List
Action taken on Study Medication
CL Item
None (1)
CL Item
Dose decreased  (2)
CL Item
Dose increased (3)
CL Item
Drug stopped (4)
CL Item
Dose interrupted (5)
Item
Suspected Relationship
text
Suspected Relationship
Code List
Suspected Relationship
CL Item
Related (1)
CL Item
Possibly related (2)
CL Item
Probably unrelated  (3)
CL Item
Unrelated (4)
Item
Corrective Therapy
text
Corrective Therapy
Code List
Corrective Therapy
CL Item
Yes (If "Yes" record on Medication form) (1)
CL Item
No (2)
Item
Do you consider this a serious adverse experience by the definitions on the tab?
integer
Serious Adverse Experience by Definition
Code List
Do you consider this a serious adverse experience by the definitions on the tab?
CL Item
Yes (If "Yes", report to SB by telephone within 24 hours) (1)
CL Item
No (2)
Item Group
Investigator´s Signature
Investigator´s Signature
Item
Investigator´s Signature
text
Date
Item
Date
date
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial